Table 1.
Cohort characteristics
| Characteristic | RA (n = 36 095) | PsA (n = 18 700) | axSpA (n = 16 524) |
|---|---|---|---|
| Women, n (%) | 25 174 (69.7) | 9991 (53.4) | 7441 (45.0) |
| Age, mean (s.d.), years | 59.08 (15.79) | 49.98 (13.96) | 43.85 (15.26) |
| Education level, n (%) | |||
| Below upper secondary | 11 447 (31.7) | 5097 (27.3) | 3996 (24.2) |
| Upper secondary or post-secondary non-tertiary | 17 068 (47.2) | 9201 (49.2) | 7704 (46.6) |
| Higher | 7580 (21.0) | 4402 (23.5) | 4825 (29.2) |
| Baseline comorbidities, n (%) | |||
| Hypertension or antihypertensive medication | 15 843 (43.9) | 6613 (35.4) | 4214 (25.5) |
| Diabetes or antidiabetic medication | 3081 (8.5) | 1560 (8.3) | 748 (4.5) |
| Coronary disease | 2050 (5.7) | 719 (3.8) | 539 (3.3) |
| Heart failure | 654 (1.8) | 106 (0.6) | 150 (0.9) |
| Atrial fibrillation | 780 (2.2) | 227 (1.2) | 197 (1.2) |
| Stroke | 1036 (2.9) | 298 (1.6) | 234 (1.4) |
| Malignancy | 2570 (7.1) | 713 (3.8) | 607 (3.7) |
| Chronic kidney disease | 405 (1.1) | 115 (0.6) | 150 (0.9) |
| Chronic respiratory disease | 2517 (7.0) | 841 (4.5) | 654 (4.0) |
| Use of DMARDs during follow-up, n (%) | |||
| Any DMARD | 28 792 (79.8) | 13 686 (73.2) | 8716 (52.7) |
| Any conventional DMARD | 27 266 (75.5) | 12 494 (66.8) | 3768 (22.8) |
| Any biologic DMARD | 11 362 (31.5) | 5782 (30.9) | 7337 (44.4) |
| Methotrexate | 24 237 (67.1) | 11 216 (60.0) | 2461 (14.9) |
| Oral glucocorticoids | 25 466 (70.6) | 8510 (45.5) | 5624 (34.0) |
Age, sex, education level, comorbidities and use of DMARDs among the RA, PsA and axSpA cohorts. axSpA: axial spondyloarthritis.